Because the enzymes acetylcholinesterase and beta-secretase are the main targets involved in AD progression, they have been widely studied, paving the way for future pharmacological treatment of the disease (Deardorff et al., 2015; Coimbra et al., 2018). This evidence concerns the gene ACHE and Alzheimer disease.